High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.
Adult
Aged
Female
Forkhead Transcription Factors
/ analysis
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Lymphocytes, Tumor-Infiltrating
/ pathology
Lymphoma, Large B-Cell, Diffuse
/ pathology
Lymphoproliferative Disorders
/ etiology
Male
Middle Aged
Organ Transplantation
/ adverse effects
Programmed Cell Death 1 Receptor
/ analysis
Retrospective Studies
Young Adult
FoxP3
PD-1
PTLD
Tumor-infiltrating lymphocytes
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
16
12
2020
accepted:
09
03
2021
revised:
05
03
2021
pubmed:
26
3
2021
medline:
29
6
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication of transplantation. In addition to reactivation of Epstein-Barr virus in immunocompromised patients, impaired tumor immunity is suggested to be a risk factor for PTLD. However, it remains unclear whether immune suppressive tumor-infiltrating lymphocytes (TILs) correlate with the occurrence or prognosis of PTLD. We analyzed TILs in 26 patients with PTLD to elucidate the clinicopathological significance of the expression of PD-1 and FoxP3, which are associated with exhausted T-cells and regulatory T-cells (Tregs), respectively. Numbers of PD-1
Identifiants
pubmed: 33765256
doi: 10.1007/s12185-021-03129-3
pii: 10.1007/s12185-021-03129-3
doi:
Substances chimiques
FOXP3 protein, human
0
Forkhead Transcription Factors
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-64Subventions
Organisme : KAKENHI
ID : 19K07450
Références
Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323(25):1767–9.
pubmed: 2247108
doi: 10.1056/NEJM199012203232510
Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222–30.
pubmed: 14974943
doi: 10.1046/j.1600-6143.2003.00325.x
Dierickx D, Tousseyn T, Sagaert X, Fieuws S, Wlodarska I, Morscio J, et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma. 2013;54(11):2433–40.
pubmed: 23442063
doi: 10.3109/10428194.2013.780655
Ghobrial IM, Habermann TM, Macon WR, Ristow KM, Larson TS, Walker RC, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation. 2005;79(2):244–7.
pubmed: 15665775
doi: 10.1097/01.TP.0000144335.39913.5C
Ferreiro JF, Morscio J, Dierickx D, Vandenberghe P, Gheysens O, Verhoef G, et al. EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features. Am J Transplant. 2016;16(2):414–25.
pubmed: 26780579
doi: 10.1111/ajt.13558
Martinez OM, Krams SM. The immune response to Epstein Barr virus and implications for posttransplant lymphoproliferative disorder. Transplantation. 2017;101(9):2009–16.
pubmed: 28376031
pmcid: 5568952
doi: 10.1097/TP.0000000000001767
Kumar D, Xu ML. Microenvironment cell contribution to lymphoma immunity. Front Oncol. 2018;8:288.
pubmed: 30101129
pmcid: 6073855
doi: 10.3389/fonc.2018.00288
Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549–62.
pubmed: 29414277
doi: 10.1056/NEJMra1702693
Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Sci (NY, NY). 2001;291(5502):319–22.
doi: 10.1126/science.291.5502.319
Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537–44.
pubmed: 19423728
pmcid: 2927090
doi: 10.1182/blood-2008-12-195792
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
pubmed: 23890059
doi: 10.1016/j.immuni.2013.07.012
Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126(19):2193–201.
pubmed: 26239088
pmcid: 4635115
doi: 10.1182/blood-2015-02-629600
Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, et al. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood. 2016;128(10):1374–81.
pubmed: 27418641
doi: 10.1182/blood-2016-02-698936
Kawamoto K, Miyoshi H, Suzuki T, Kiyasu J, Yokoyama S, Sasaki Y, et al. Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients. Hematol Oncol. 2018;36(3):591–9.
pubmed: 29602174
doi: 10.1002/hon.2506
Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6(4):345–52.
pubmed: 15785760
doi: 10.1038/ni1178
Morgan ME, van Bilsen JH, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol. 2005;66(1):13–20.
pubmed: 15620457
doi: 10.1016/j.humimm.2004.05.016
Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother. 2007;56(11):1687–700.
pubmed: 17571260
doi: 10.1007/s00262-007-0343-y
deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012;18(11):3022–9.
pubmed: 22510350
doi: 10.1158/1078-0432.CCR-11-3216
Styczynski J, Velden W, Fox CP, Engelhard D, Camara R, Cordonnier C, et al. Management of Epstein–Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European conference on infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–11.
pubmed: 27365460
pmcid: 5004459
doi: 10.3324/haematol.2016.144428
Trappe RU, Choquet S, Dierickx D, Mollee P, Zaucha JM, Dreyling MH, et al. International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial. Am J Transplant. 2015;15(4):1091–100.
pubmed: 25736912
doi: 10.1111/ajt.13086
Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107(8):3053–7.
pubmed: 16254143
doi: 10.1182/blood-2005-01-0377
Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica. 2007;92(2):273–4.
pubmed: 17296588
doi: 10.3324/haematol.10595
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.
pubmed: 14504078
doi: 10.1182/blood-2003-05-1545
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–67.
pubmed: 25113753
pmcid: 4979083
doi: 10.1200/JCO.2013.54.8800
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
pubmed: 23208313
doi: 10.1038/bmt.2012.244
Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704.
pubmed: 27269947
pmcid: 5019749
doi: 10.1200/JCO.2015.65.9789
Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865–74.
pubmed: 27084740
doi: 10.1158/1078-0432.CCR-15-1507
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.
pubmed: 22658128
pmcid: 3563263
doi: 10.1056/NEJMoa1200694
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.
pubmed: 25428505
pmcid: 4246418
doi: 10.1038/nature13954
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50.
pubmed: 29686425
pmcid: 5998822
doi: 10.1038/s41591-018-0014-x
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–23.
pubmed: 28187290
pmcid: 5391692
doi: 10.1016/j.cell.2017.01.017
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–99.
pubmed: 26205583
pmcid: 4889009
doi: 10.1038/nri3862
Moran J, Dean J, De Oliveira A, O’Connell M, Riordan M, Connell J, et al. Increased levels of PD-1 expression on CD8 T cells in patients post-renal transplant irrespective of chronic high EBV viral load. Pediatr Transplant. 2013;17(8):806–14.
pubmed: 24118875
doi: 10.1111/petr.12156
Marcelis L, Tousseyn T. The tumor microenvironment in post-transplant lymphoproliferative disorders. Cancer Microenviron. 2019;12(1):3–16.
pubmed: 30680693
pmcid: 6529504
doi: 10.1007/s12307-018-00219-5
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10.
pubmed: 30646912
pmcid: 6332843
doi: 10.1186/s12943-018-0928-4
Nakayama S, Yokote T, Akioka T, Hiraoka N, Nishiwaki U, Miyoshi T, et al. Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified. Blood advances. 2017;1(8):486–93.
pubmed: 29296965
pmcid: 5728452
doi: 10.1182/bloodadvances.2016000885
Berglund D, Kinch A, Edman E, Backlin C, Enblad G, Larsson E, et al. Expression of intratumoral forkhead box protein 3 in posttransplant lymphoproliferative disorders: clinical features and survival outcomes. Transplantation. 2015;99(5):1036–42.
pubmed: 25211518
doi: 10.1097/TP.0000000000000415
Shaknovich R, Basso K, Bhagat G, Mansukhani M, Hatzivassiliou G, Murty VV, et al. Identification of rare Epstein–Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling. Haematologica. 2006;91(10):1313–20.
pubmed: 17018379
Morscio J, Dierickx D, Tousseyn T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol. 2013;2013:150835.
pubmed: 23690819
pmcid: 3649442
doi: 10.1155/2013/150835
Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M, McKnight JL. Evidence for restricted Epstein–Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood. 1993;81(5):1393–403.
pubmed: 8382973
doi: 10.1182/blood.V81.5.1393.1393
Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Yamaoka K, Shimizu T, et al. Restoration of decreased T Helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Front Immunol. 2018;9:621.
pubmed: 29670617
pmcid: 5893782
doi: 10.3389/fimmu.2018.00621
Takanashi S, Aisa Y, Ito C, Arakaki H, Osada Y, Amano Y, et al. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression. Rheumatol Int. 2017;37(10):1629–33.
pubmed: 28676912
doi: 10.1007/s00296-017-3764-8
Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34(2):324–56.
pubmed: 28004361
doi: 10.1007/s12325-016-0451-1
Lipson EJBS, Moore J Jr, Jang S, Patel MJ, Zachary AA, Pardoll DM, Taube JM, Drake CG. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374(9):896–8.
pubmed: 26962927
pmcid: 4850555
doi: 10.1056/NEJMc1509268
Wada F, Kondo T, Nakamura M, Chonabayashi K, Nishikori M, Hishizawa M, et al. Successful treatment of Hodgkin lymphoma-like EBV-associated post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation with nivolumab. Ann Hematol. 2020;99(4):887–9.
pubmed: 32052134
doi: 10.1007/s00277-020-03960-4
Schecter JM, Hoehn D, Imus P, Alma E, Lentzsch S, Alobeid B, et al. Pathologic and clinical features of CD30+ post-transplant lymphoproliferative disorders: a large retrospective single institutional study. Blood. 2013;122(21):4333.
doi: 10.1182/blood.V122.21.4333.4333
Gandhi M, Ma S, Smith SM, Nabhan C, Evens AM, Winter JN, et al. Brentuximab vedotin (BV) plus rituximab (R) as frontline therapy for patients (Pts) with Epstein Barr Virus (EBV)+ and/or CD30+ lymphoma: phase I results of an ongoing phase I–II study. Blood. 2014;124(21):3096.
doi: 10.1182/blood.V124.21.3096.3096
Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–402.
pubmed: 25573987
doi: 10.1182/blood-2014-09-598763
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–65.
pubmed: 31693429
doi: 10.1200/JCO.19.00172
Zimmermann H, Trappe RU. Therapeutic options in post-transplant lymphoproliferative disorders. Ther Adv Hematol. 2011;2(6):393–407.
pubmed: 23556105
pmcid: 3573421
doi: 10.1177/2040620711412417